Stapled Peptidomimetic Therapeutics

Engineering the Next Generation of Precision Peptide Medicine

Mount BioTherapeutics is an early-stage biopharmaceutical company advancing a proprietary stapled peptidomimetic platform targeting high-burden metabolic and neurodegenerative diseases with unmet clinical need.

Explore Our Platform Investor Inquiries
Scroll
3
Provisional Patent Applications
12+
Novel Therapeutic Candidates
2
SBIR Grant Applications
2027
Target Acquisition Exit
About the Company

A Capital-Efficient Model
Built for Strategic Exit

Mount BioTherapeutics LLC is an early-stage biotechnology company developing a novel class of stabilized peptidomimetic therapeutics through a capital-efficient, CRO-execution model. We own the science and the IP - established partners execute the chemistry and pharmacology.

Our approach targets conditions where existing peptide-based therapies fail due to metabolic instability, poor receptor selectivity, or inadequate tissue penetration. Through proprietary macrocyclization architecture, we engineer peptide-derived molecules with drug-like durability and precise target engagement.

The company is structured for a defined acquisition exit by late 2027, targeting strategic buyers in the metabolic disease and neurotherapeutics space. Value creation is driven by IP estate strength, non-dilutive government grant funding, and an independent scientific advisory board - not by internal infrastructure.

01
Proprietary IP Estate
Three provisional patent applications filed covering core compound series and platform carrier technology. Non-provisional conversion underway toward 2027 deadline.
02
Non-Dilutive Funding
Active pursuit of SBIR Phase I awards from NIA and NIDDK, supplemented by targeted foundation grant strategy.
03
Scientific Advisory Board
Assembling a credentialed SAB of 2-3 domain-expert scientists spanning peptide chemistry, GI physiology, and neurodegeneration.
04
Computational Modeling
Structural modeling package supports design rationale and candidate optimization across the full pipeline, informing both IP prosecution and grant applications.
Technology Platform

The Dual-Shield Architecture

Our proprietary platform employs all-hydrocarbon macrocyclization to confer alpha-helical stability, protease resistance, and enhanced membrane permeability to peptide-derived therapeutic candidates - properties unattainable in linear peptide formats.

Core Architecture
Dual-Shield™ Stapling System
Proprietary double-stapling configuration providing superior conformational constraint versus single-staple approaches. Engineered to maintain receptor-competent geometry while resisting proteolytic degradation in physiological environments.
Hydrocarbon Macrocyclization
Extended Platform
HelixLock™ Compound Series
A broad series of stapled candidates across multiple peptide scaffolds - including metabolic hormone analogs and neuropeptide-derived sequences - enabling rapid pipeline expansion from a single technology core.
Multi-Scaffold Applicability
Delivery Innovation
Macromolecular Carrier Platform
Proprietary carrier technology designed to extend systemic half-life and modulate biodistribution of stapled peptide payloads, addressing pharmacokinetic limitations that constrain conventional peptide drug formats.
Proprietary IP - Confidential
Development Pipeline

Lead Assets & Indication Coverage

Asset Indication Stage Mechanism
MBT-103
Lead Candidate
 Refractory Gastroparesis
Preclinical Design
AMY1/3 Antagonism
MBT-114
Neurodegeneration
 Alzheimer's Disease
Preclinical Design
ApoE/Aβ Blocker
MBT-107
CNS / Pain
 Migraine Prevention
Preclinical Design
CGRP-R Antagonism
MBT-106 / 110 / 116
HelixLock Series
 Metabolic / Bone / Obesity
Preclinical Design
Multi-Target Agonism
CryoSurge ELP
Carrier Platform
 Platform Technology
Preclinical Design
Macromolecular Delivery

Detailed pipeline data, binding projections, and structural modeling available under NDA to qualified parties.

Business Strategy

Designed for Acquisition

Mount BioTherapeutics operates on a defined exit thesis: build maximum IP and scientific credibility with minimum capital consumption, then position for strategic acquisition by a mid-to-large pharma or specialty biotech acquirer in the metabolic or neurology space.

The CRO-execution model eliminates the overhead of internal wet labs while retaining full IP ownership. Every dollar deployed goes toward patentable science, validated data packages, and credentialed scientific relationships - the three assets acquirers pay for.

  • 2026 SBIR Phase I submissions (NIA, NIDDK) - SAB assembly - Computational model package completion
  • Q1 2027 Non-provisional patent filings (3 applications) - SBIR Phase I award decisions
  • Mid 2027 Lead asset in vitro validation data - CRO pharmacology readouts - Partnering conference outreach
  • Late 2027 Targeted acquisition exit - $20-40M upfront range with milestone structure
Get in Touch

Ready to Learn More?

We welcome conversations with strategic acquirers, institutional investors, SBIR program officers, and prospective scientific advisors. A confidential data package is available to qualified parties under NDA.

Company Mount BioTherapeutics LLC
Principal Investigator Austin Lee Mount, Cell & Molecular Biology
Location Zephyrhills, FL
Email austin@mountbiotherapeutics.com
Therapeutic Focus Metabolic Disease & Neurodegeneration
Exit Target Strategic Acquisition - Late 2027

Confidential pipeline details, IP documentation, and scientific data packages available under executed NDA